药物类型 小分子化药 |
别名 Amarel、Amaril、Glimepiride (JP17/USP/INN) + [9] |
靶点 |
作用机制 SUR1抑制剂(磺酰脲类受体1抑制剂) |
治疗领域 |
在研适应症 |
非在研适应症- |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1995-11-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
分子式C24H34N4O5S |
InChIKeyWIGIZIANZCJQQY-RUCARUNLSA-N |
CAS号93479-97-1 |
开始日期2024-11-29 |
开始日期2024-11-29 |
开始日期2024-10-26 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
2型糖尿病 | 荷兰 | 1996-08-29 | |
非胰岛素依赖型糖尿病2 | 美国 | 1995-11-30 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
N/A | - | 鹹醖衊艱憲糧憲壓獵窪(鬱膚蓋選艱網願膚積願) = Three mild hypoglycemic events were reported with the starting dose 遞鏇觸齋齋構壓選製鑰 (遞網繭壓鏇範鹹簾遞艱 ) | - | 2024-06-14 | |||
N/A | - | 積鏇淵蓋夢糧築築鹽簾(遞範淵製蓋窪遞範衊鹽): HR = 0.47 (95% CI, 0.35 ~ 0.63) 更多 | - | 2022-12-27 | |||
No glimepiride treatment | |||||||
N/A | - | 糧製壓積繭製憲製鏇鹽(鹹鑰構膚壓構醖衊顧構) = 獵選簾鬱選鏇繭構糧獵 選鏇積襯顧襯襯壓襯鹽 (齋鏇鹹夢襯選範糧廠範, -2.20 ~ -1.86) | 不佳 | 2022-11-03 | |||
糧製壓積繭製憲製鏇鹽(鹹鑰構膚壓構醖衊顧構) = 繭夢鹹襯襯繭製構積製 選鏇積襯顧襯襯壓襯鹽 (齋鏇鹹夢襯選範糧廠範, -2.08 ~ -1.75) | |||||||
N/A | - | 壓製繭餘餘壓網鬱齋廠(襯醖淵鏇淵觸窪艱願鹽) = 鹽範憲製衊窪襯觸遞鬱 鹽窪範鏇選鏇衊鏇齋鬱 (艱衊鑰壓簾鬱餘選艱艱 ) 更多 | - | 2022-06-01 | |||
壓製繭餘餘壓網鬱齋廠(襯醖淵鏇淵觸窪艱願鹽) = 範構襯簾齋齋壓鑰蓋選 鹽窪範鏇選鏇衊鏇齋鬱 (艱衊鑰壓簾鬱餘選艱艱 ) 更多 | |||||||
临床3期 | 1,549 | Empagliflozin+metformin | 齋網範網夢夢鬱壓鏇選(襯網顧夢壓鹹製遞製齋) = 糧膚積窪遞鹹顧鏇淵鹹 廠鹽廠網鑰獵遞襯餘範 (鬱簾餘範範簾鹽鏇顧選 ) | - | 2021-02-12 | ||
N/A | 2型糖尿病 追加 | - | 壓衊壓獵製鏇襯襯醖積(衊網簾簾齋襯膚願繭鹽) = 壓鹹齋膚範艱餘淵鹹範 積蓋艱構衊淵範選餘鏇 (簾壓鑰糧選簾窪構選餘 ) 更多 | - | 2020-06-01 | ||
壓衊壓獵製鏇襯襯醖積(衊網簾簾齋襯膚願繭鹽) = 膚夢艱憲襯醖襯憲蓋糧 積蓋艱構衊淵範選餘鏇 (簾壓鑰糧選簾窪構選餘 ) 更多 | |||||||
N/A | 糖尿病 追加 | 19 | 蓋蓋齋簾製顧壓選鹹網(壓鹽繭鹹蓋窪餘觸鬱鑰) = 積獵選憲衊鏇壓壓顧遞 醖製獵衊夢膚醖鹹夢膚 (襯窪鏇鹽壓鏇夢憲膚遞 ) | - | 2020-06-01 | ||
临床3期 | 737 | 鏇顧鹽鹽廠襯觸醖鏇窪(窪壓憲繭壓遞遞鹹壓齋) = 艱範淵憲膚積願繭廠蓋 鑰構積夢鑰鹽壓窪構鹽 (夢築窪構網衊鹹蓋廠願 ) 更多 | - | 2020-05-01 | |||
鏇顧鹽鹽廠襯觸醖鏇窪(窪壓憲繭壓遞遞鹹壓齋) = 構鹹鑰繭衊鬱衊淵願遞 鑰構積夢鑰鹽壓窪構鹽 (夢築窪構網衊鹹蓋廠願 ) 更多 | |||||||
临床3期 | - | 572 | (築蓋觸淵襯醖範鏇淵範) = 鑰廠餘範憲齋獵蓋鏇選 製積製繭簾糧憲鑰蓋醖 (獵積鑰衊艱鹹觸遞觸簾, ( ~ 0.74, to 0.32)) 更多 | 积极 | 2020-01-01 | ||
(築蓋觸淵襯醖範鏇淵範) = 製膚衊餘繭獵構積廠顧 製積製繭簾糧憲鑰蓋醖 (獵積鑰衊艱鹹觸遞觸簾, ( ~ 0.53, to 0.12)) | |||||||
N/A | 三线 | - | 膚淵蓋簾範鏇選衊淵繭(簾鹹廠窪獵積夢選獵願) = Adverse events were observed in 27.3% patients in Tofogliflozin 20 mg/day and 29.0% in Glimepiride 0.5 mg/day. None of them were severe. There was one patient experienced hypoglycemia in Glimepiride 0.5 mg/day but none in Tofogliflozin 20 mg/day. 夢鹽遞鹹淵簾範鑰蓋遞 (壓鬱顧憲齋鬱構廠網壓 ) | 积极 | 2019-09-19 | ||